The conversation is a humorous discussion about a Lego microneedling set for hair loss, comparing it to a wax pen. No specific treatments are mentioned.
The conversation is about a user trying topical melatonin mixed with minoxidil to reduce hair shedding after not seeing desired results with finasteride and minoxidil alone. Another user suggests that instead of daily updates, the original poster should share their results after a few weeks.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
A 24-year-old uses microneedling, tretinoin, topical and oral minoxidil, and oral finasteride for hair growth, noticing baby hair growth and initial side effects that resolved. Another user shares a similar regimen, excluding finasteride.
The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A user shared a 3-month hair regrowth progress using minoxidil and microneedling. They also use rosemary oil and plan to continue treatment for at least 6-9 more months.
A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
The conversation discusses hair loss treatments, specifically the effectiveness and legitimacy of low-level laser therapy (LLLT) devices under $200. The user has seen positive results with finasteride, minoxidil, ketoconazole, microneedling, and scalp massages, and seeks advice on affordable LLLT options.
A user shared their successful hair regrowth journey using 1mg finasteride daily, 1ml minoxidil nightly, and weekly 1.5mm microneedling. They reported some side effects like reduced semen thickness but are satisfied with the results and recommend topical minoxidil over oral.
Combining minoxidil 5%, tazarotene 0.1% cream, and lumigan for hair loss treatment is discussed. The conversation focuses on the safety and effectiveness of using these treatments together.
A user is considering using compounded Minoxidil with Tretinoin from Medical Wellness Center to improve hair growth. They are also curious about the effects of higher Minoxidil doses and adding Tretinoin to their regimen.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Addressing hair loss by focusing on posture, blood flow, and craniofacial development. Methods include improving posture, cardiovascular activity, scalp massages, healthy diet, meditation, using minoxidil, and addressing craniofacial issues.
A 20-year-old using 1 mg finasteride, 2 ml topical minoxidil, tretinoin, and microneedling for hair loss shows progress after three months, with thicker hair and temple regrowth. No side effects reported, and the user is considering switching to oral minoxidil.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
The user is concerned about hair regrowth after 6 weeks on 5mg Minoxidil, 1mg Finasteride, 50mg levothyroxine, Keto, and dermarolling every 10 days. They notice baby hairs but are worried about increased shedding and seek reassurance.
The conversation humorously discusses using off-label drugs like Minoxidil, finasteride, and RU58841 for hair growth. It jokes about the brain absorbing these treatments for maximum keratin production.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
A user who was losing their hair and found an effective solution; they asked for opinions on it and discussed treatments such as Minoxidil, Finasteride, and RU58841, as well as SMP.
The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.